FDA warns Mountain Meadow Herbs
This article was originally published in The Tan Sheet
Executive Summary
FDA makes good on its promise to follow up on enforcement actions by sending a warning letter to Mountain Meadow Herbs after the firm inadequately corrected problems identified during an inspection. In a Sept. 21 letter, the agency warns the Kalispell, Mont., supplement firm to revise claims that make its supplements Natural Attention-Aid, Winter-Immune Booster, Herbal Respiratory and othersunapproved new drugs. The letter follows several notices the agency sent the firm after it inspected its manufacturing facility and notified it of similar concerns. Mountain Meadow Herbs revised its claims in response to the first notice, but the changes did not satisfy FDA. Commissioner Margaret Hamburg said Aug. 6 the agency will follow up on warning letters and other enforcement actions. FDA also set a firm 15-day post-inspection deadline for firms to respond to inspections (1"The Tan Sheet" Aug. 10, 2009)
You may also be interested in...
FDA Enforcement Follow-Through Could Thin Out Violators
FDA's emphasis on follow-through in its revamped enforcement strategy may help weed out bad actors from legitimate industry
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.